Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15939976 | 1.00 | CYP1A2 (0.30) | CYP1A2 | |
| SCHEMBL14783831 | 1.00 | CYP1A2 (0.30) | CYP1A2 | |
| SCHEMBL14794944 | 0.92 | CYP1A2 (0.30) | CYP1A2 | |
| SCHEMBL14783873 | 0.73 | CFTR (0.41) | — | |
| SCHEMBL14783388 | 0.72 | HDAC6 (0.34) | — | |
| SCHEMBL14783806 | 0.72 | CFTR (0.42) | — | |
| SCHEMBL15939851 | 0.71 | CFTR (0.40) | CYP1A2 | |
| SCHEMBL15939844 | 0.71 | CFTR (0.40) | CYP1A2 | |
| SCHEMBL14783509 | 0.70 | CFTR (0.44) | — | |
| SCHEMBL14794943 | 0.70 | CFTR (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755967-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | claimed |
| US-9034879-B2 | Heterocyclic compounds for the treatment of CF | NOVARTIS AG (CH) | 2015-05-19 | — | — | US | claimed |
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | claimed |
| CN-103946221-A | Heterocyclic compounds for the treatment of cystic fibrosis | NOVARTIS AG | 2014-07-23 | — | — | CN | claimed |
| EP-2755967-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-9034879-B2 | Heterocyclic compounds for the treatment of CF | NOVARTIS AG (CH) | 2015-05-19 | — | — | US | disclosed |
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| CN-103946221-A | Heterocyclic compounds for the treatment of cystic fibrosis | NOVARTIS AG | 2014-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | CFTR, OPRD1, OPRK1 | CYP1A2 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.